CENCORA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.9 USD | -0.44% |
|
-2.12% | +8.06% |
| 05-08 | Jefferies Adjusts Price Target on Cencora to $230 From $235 | MT |
| 05-03 | Wells Fargo Adjusts Cencora Price Target to $236 From $235 | MT |
| Sales 2024 * | 291B 23,037B | Sales 2025 * | 310B 24,589B | Capitalization | 44.27B 3,510B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.01B 159B | Net income 2025 * | 2.33B 185B | EV / Sales 2024 * | 0.16 x |
| Net Debt 2024 * | 989M 78.43B | Net cash position 2025 * | 624M 49.5B | EV / Sales 2025 * | 0.14 x |
| P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
18.6
x | Employees | 44,000 |
| Yield 2024 * |
0.93% | Yield 2025 * |
0.95% | Free-Float | 58.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cencora, Inc.
More recommendations
More press releases
More news
| 1 day | -0.44% | ||
| 1 week | -2.12% | ||
| Current month | -7.16% | ||
| 1 month | -5.15% | ||
| 3 months | -4.16% | ||
| 6 months | +14.18% | ||
| Current year | +8.06% |
1 week
220.68
226.18
1 month
220.68241.36
Current year
204.53246.75
1 year
163.37246.75
3 years
111.34246.75
5 years
72.06246.75
10 years
67.31246.75
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Collis
CEO | Chief Executive Officer | 62 | 31/12/93 |
James Cleary
DFI | Director of Finance/CFO | 61 | 31/01/15 |
Jennifer Dubas
CMP | Compliance Officer | - | 31/08/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kathleen Hyle
BRD | Director/Board Member | 65 | 12/05/10 |
| Director/Board Member | 74 | 24/09/08 | |
D. Mark Durcan
BRD | Director/Board Member | 62 | 07/09/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.85% | 2 M€ | +21.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 221.9 | -0.44% | 1,522,222 |
| 13/05/24 | 222.9 | -0.75% | 1,060,591 |
| 10/05/24 | 224.6 | +0.23% | 943,908 |
| 09/05/24 | 224.1 | -0.01% | 927,628 |
| 08/05/24 | 224.1 | -1.16% | 2,401,794 |
Delayed Quote Nyse, May 14, 2024 at 09:00 pm
More quotes
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
Calendar
30/07/2024
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
221.9
USD
Average target price
254.5
USD
Spread / Average Target
+14.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 44.27B | |
| -5.51% | 181B | |
| +2.33% | 112B | |
| -3.62% | 67.92B | |
| +1.52% | 50.1B | |
| +9.39% | 40.41B | |
| +23.35% | 31.95B | |
| +0.67% | 25.82B | |
| +17.27% | 25.29B | |
| -1.42% | 24.68B |
- Stock Market
- Equities
- COR Stock
